Table 2.
Univariate analysis of factors associated with the FT group compared with those of the ST group.
| Characteristic | FT N=7 |
ST N=10 |
P value |
|---|---|---|---|
| Age, m, median (IQR) | 70.00(20.00,146,00) | 22.00(12.26,39.00) | 0.143 |
| Male sex | 3(42.86%) | 6(60%) | 0.637 |
| Duration of hospital stay before detected, d, median (IQR) | 27.00(12.00,53.00) | 19.00(6.75,30.00) | 0.329 |
| Previous hospital admission within 6 m | 2(28.57%) | 7(70.00%) | 0.153 |
| Neurosurgery | 7(100.00%) | 8(80.00%) | 0.485 |
| Days from first neurosurgery to diagnosis, d, median (IQR) | 9.00(5.00,25.00) | 17.50(2.25,24.00) | 0.845 |
| Mechanical ventilation | 7(100.00%) | 5(50.00%) | 0.044 |
| Indwelling central venous catheter | 6(85.71%) | 5(50.00%) | 0.304 |
| Indwelling ventricular drainage | 4(57.15%) | 3(30.00%) | 0.644 |
| Receiving immunosuppressive therapy | 1(14.29%) | 0(0.00%) | 0.412 |
| Co-infections with other bacteria or fungi | 2(28.57%) | 4(40.00%) | 1.000 |
| Intrathecal injection | 0(0.00%) | 3(30.00%) | 0.228 |
| Previous antibiotic therapy within 30 d | |||
| Cephalosporins | 7(100.00%) | 8(80.00%) | 0.485 |
| β-Lactam-β-Lactamase Inhibitor | 4(57.15%) | 2(20.00%) | 0.162 |
| Carbapenems | 6(85.71%) | 5(50.00%) | 0.304 |
| Vancomycin | 4(57.15%) | 7(70.00%) | 0.644 |
| Clinical features of infections | |||
| Duration of fever, d, median (IQR) | 19.90 ± 10.01 | 20.43 ± 12.00 | 0.923 |
| White cell count, ×10^9/L, median (IQR) | 14.85 ± 4.45 | 25.34 ± 9.88 | 0.031 |
| Neutrophil, %, median (IQR) | 82.30(76.70,86.10) | 69.70(58.60,80.70) | 0.107 |
| C-reactive protein, mg/L, median (IQR) | 76.87 ± 48.31 | 103.43 ± 54.90 | 0.308 |
| Procalcitonin, ng/ml, median (IQR) | 1.87(1.07,4.36) | 0.14(0.90,2.18) | 0.045 |
| Interleukin 6, pg/ml, median (IQR) | 47.58(38.55,186.10) | 47.58(32.07,235.70) | 0.210 |
| White cell count in CSF,×10^6/L, median (IQR) | 1200.00(1000.00,2470.00) | 1080.00(198.75,2500.00) | 0.463 |
| Protein in CSF, mg/L, median (IQR) | 4960.00(3577.90,7980.20) | 2440.25(1415.48,4541.00) | 0.032 |
| Glucose in CSF, mmol/L, median (IQR) | 0.10(0.00,1.70) | 1.20(0.18,2.15) | 0.184 |
| Sepsis | 5(71.43%) | 2(20.00%) | 0.058 |
| Septic shock | 6(85.71%) | 1(10.00%) | 0.004 |
| Hospitalization ward | 0.134 | ||
| Pediatric intensive care unit | 6(85.71%) | 4(40.00%) | |
| General wards | 1(14.29%) | 6(60.00%) | |
| Detection with CRAB | 7(100.00%) | 5(50.00%) | 0.044 |
| Duration of targeted antibiotic treatment, d, median (IQR) | 17.00(13.00,42.00) | 34.00(22.25,42.00) | 0.186 |
ST, successful treatment group; FT, failed treatment group; CRAB, carbapenem-resistant Acinetobacter baumannii; CSF, cerebrospinal fluid.